GlassScriptPhysician profile
Alma Alicia Lujan
NPI 1215673025
$1,275.30
in general payments reported to CMS, 2019-2025
27 companies · $755 in 2025
The $755 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $104 · 2024: $416 · 2025: $755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $794 · Education: $377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $794.23 |
| Education | $376.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $218.36 | 2024-2025 | Jakafi, Zynyz, Monjuvi |
| Abbvie INC. | $134.07 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $116.90 | 2022-2025 | |
| Seagen INC. | $99.99 | 2025 | |
| Celgene Corporation | $84.50 | 2024-2025 | Reblozyl |
| Ultragenyx Pharmaceutical INC. | $77.93 | 2022 | |
| Glaxosmithkline, LLC. | $75.12 | 2024-2025 | Zejula, Jemperli, Ojjaara |
| Bayer Healthcare Pharmaceuticals INC. | $51.63 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.16 | 2024-2025 | Alunbrig |
| Lilly USA, LLC | $35.87 | 2025 | Verzenio, Jaypirca |
| Gilead Sciences, INC. | $28.97 | 2025 | Trodelvy |
| Genentech USA, INC. | $27.87 | 2024 | Phesgo, Itovebi, Perjeta |
| Aveo Pharmaceuticals, INC. | $22.48 | 2025 | |
| Alexion Pharmaceuticals, INC. | $22.09 | 2024 | Ultomiris |
| Geron Corporation | $22.06 | 2025 | Rytelo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $21.75 | 2025 | Cabometyx |
| Merck Sharp & Dohme LLC | $21.46 | 2024 | Keytruda |
| Kite Pharma, INC. | $21.02 | 2025 | Yescarta |
| Novo Nordisk INC | $20.14 | 2024 | |
| Astellas Pharma US INC | $19.10 | 2025 | Xtandi |
| Genzyme Corporation | $18.43 | 2024 | |
| Springworks Therapeutics, INC. | $16.92 | 2025 | Ogsiveo |
| Daiichi Sankyo INC. | $16.27 | 2024 | Enhertu |
| Adaptive Biotechnologies Corporation | $16.17 | 2025 | Clonoseq |
| Pfizer INC. | $15.67 | 2025 | |
| Adc Therapeutics America, INC. | $15.22 | 2025 | |
| Organon LLC | $14.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alma Lujan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.